Rodman & Renshaw Announces Analyst Discussion with Cleveland BioLabs, Inc. and Dr. Craig Vanderwagen, a Partner with Martin, Blanck & Associates

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), a leading full service investment bank for growth companies today announced that on August 10, 2010, Rodman will host an analyst discussion in its media center with Michael Fonstein, Ph.D., President and Chief Executive Officer, Andrei Gudkov, Ph.D., D. Sci., Chief Scientific Officer, of Cleveland BioLabs, Inc. and Craig Vanderwagen, MD, a Partner with Martin, Blanck & Associates, a federal health services consulting firm based in Falls Church, Virginia.

Dr. Vanderwagen offers unique and groundbreaking experience in biodefense, domestic disaster preparedness and response, international humanitarian and disaster response, federal health delivery systems, innovative organization development and evaluation, and cross-cultural health care.

The event will be hosted by Simos Simeonidis, Ph.D., Managing Director and Senior Biotechnology Analyst, of Rodman & Renshaw, LLC. The topics to be covered will include a discussion of the company’s pipeline compounds, and will include the latest update on CBLI’s lead program, CBLB502, currently in development for the treatment of Acute Radiation Syndrome.

The analyst discussion will take place at Rodman & Renshaw’s offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020) at 4:30PM ET on August 10^th, 2010. To attend, please RSVP to Marta Wypych at mwypych@rodm.com. This event will also be webcasted live at Rodman TV (www.rodm.tv). Advance registration is required at least 30 minutes prior to the start of the broadcast. The event can also be accessed via conference line. Investors should contact your sales representative at Rodman & Renshaw for the dial-in information or visit Rodman TV for the archived video - which will be available 24 hours after the completion of the event.

Background of Participants:

Craig Vanderwagen, MD

From August 2006 until July 2009, Dr. Vanderwagen was the founding Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services. In this role he was responsible for the leadership and development of a new organization whose mission was preparing the Nation for response and recovery from public health and other health disasters whether natural or manmade. The organization was initiated after hurricane Katrina and formalized after the passage of the Pandemic and All Hazards Preparedness Act. The Act empowered the ASPR as the lead for all federal public health and medical response in disasters. It also initiated the Biomedical Acquisition, Research, and Development Authority for the development and acquisition of medical countermeasures (preventives, treatments, and diagnostics) for the civilian population. Lastly the funding of grants for development of state and local hospital preparedness activities became a major element of the preparedness activities in ASPR.

Dr. Vanderwagen had a distinguished 28 year career in public service as a commissioned officer in the United States Public Health Service (USPHS), Department of Health and Human Services (HHS). His assignments prior to becoming Assistant Secretary included many deployments in disaster environments. These included lead federal health official in Louisiana after Katrina from August-November, 2005; lead public health official and senior officer aboard the USNS Mercy in Indonesia after the tsunami in 2005; Director of Primary Care and Public Health for the Ministry of Health in Iraq from September 2003-March, 2004; consultant to the Pan American Health Organization in Honduras after Hurricane Mitch in 1999; and Medical Director for Project Provide Refuge (joint DOD-HHS Kosovar refugee assistance) in 1999.

These deployed assignments however were in addition to his regular duties in the Indian Health Service where during his 25 years of service, he held a number of responsible positions and was the agency’s Chief Medical Officer as his last assignment. During his career with Indian Health Service, Dr. Vanderwagen provided leadership in the uses of electronic health records, implementation of the use of best practices to combat chronic diseases, and was an early supporter of, and the agency’s lead negotiator for a majority of the early Self Governance Compacts.

Dr. Vanderwagen is a family physician who believes passionately in the union of public health and clinical medicine.

Simos Simeonidis, Ph.D.

Simos Simeonidis, Ph.D., is a Managing Director and Senior Biotechnology Analyst. Dr. Simeonidis joined Rodman from First Albany Capital where he was a Vice President and Senior Biotechnology Analyst covering the small and mid-cap biotechnology and specialty pharmaceuticals sector. Prior to First Albany Capital, Dr. Simeonidis was an associate biotechnology analyst at Morgan Stanley and before that, he was an Associate Director in the Business Development/Licensing and Strategic Planning groups at Novartis. Dr. Simeonidis also brings additional industry experience through his tenure at GlaxoSmithKline’s Global Commercial Strategy group.

Prior to his role as a research analyst, Dr. Simeonidis was a faculty member at Harvard Medical School and the Beth Israel Deaconess Medical Center. His work on the transcriptional regulation of gene expression through the NF-kB/IkB pathway and in signal transduction in cancer, inflammation and infectious disease led to grant awards and numerous articles in leading peer-reviewed biomedical journals. He has presented his work at leading medical and scientific conferences and has held academic appointments at Columbia University, Northeastern Illinois University and Boston College.

Dr. Simeonidis received his BS in Biology from Loyola University in Chicago, and his MA, MPhil and PhD in Cellular, Molecular and Biophysical Studies from Columbia University’s College of Physicians and Surgeons, where he graduated first in his class, worked on the regulation of gene expression through the NF-kB/IkB pathway, and cloned one of the three NF-kB inhibitory genes, IkB epsilon. Dr. Simeonidis completed his postdoctoral fellowship at Harvard Medical School and the Brigham and Women’s Hospital in the laboratory of Dr. Tucker Collins, where he worked on signal transduction pathways in inflammation and atherosclerosis, and has also received his MBA in Healthcare Management at The Wharton School.

Background of Management:

Michael Fonstein, Ph.D.

Dr. Fonstein has served as Cleveland BioLabs’s Chief Executive Officer and President and as a director since the company’s inception in June 2003. Prior to this he served as Director of the DNA Sequencing Center at the University of Chicago from its creation in 1994 to 1998, when he left to found Integrated Genomics, Inc. located in Chicago, Illinois. He served as CEO and President of Integrated Genomics from 1997 to 2003. Dr. Fonstein has won several business awards, including the Incubator of the Year Award from the Association of University Related Research Parks. He was also the winner of a coveted KPMG Illinois High Tech Award.

Andrei Gudkov, Ph.D.

Dr. Gudkov has served as Cleveland BioLabs’s Chief Scientific Officer and as a director since the company’s inception in June 2003. Prior to 1990, he worked at The National Cancer Research Center in Moscow (USSR) where he led a broad research program focused on virology and cancer drug resistance. In 1990, he reestablished his lab at the University of Illinois at Chicago where he became a tenured faculty member in the Department of Molecular Genetics. His lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic where he became Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. In 2007, Dr. Gudkov accepted the position of Senior VP Basic Science and Chair, Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, NY. Dr. Gudkov is not employed full time by the company, but rather divides time between work for CBLI and for Roswell Park.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a pipeline of drugs for multiple medical and defense applications. CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

About Rodman & Renshaw Capital Group, Inc.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005.

For more information visit Rodman & Renshaw on the Internet at www.rodm.com.

MEMBER FINRA, SIPC